Anthem Biosciences Ltd (ANTHEM) is currently trading at 924.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Anthem Biosciences Limited specializes in manufacturing specialty organic molecules and biologically active peptides, catering primarily to the drug and specialty chemicals industries. The company reported a decline in quarterly revenue, with Q3FY26 showing a 15% year-over-year decrease compared to Q3FY25, while maintaining robust EBITDA margins around 41.8%. Despite revenue challenges, Anthem focused on margin improvement, achieving an EBITDA growth of 22.6% for 9MFY26 compared to 9MFY25. The strategic emphasis on backward integration and cost control is evident, as shown by a reduction in material costs, thus improving overall profitability. Anthem's expanding scope into biosimilars and the strong performance of its CRDMO segment highlight its dedication to innovative biotech solutions.

Over the past 52 weeks, Anthem Biosciences Ltd has traded between a low of ₹579.45 and a high of ₹927.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Anthem Biosciences Ltd has a market capitalization of approximately 49,275.97. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Anthem Biosciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 83.09 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 49,275.97 Cr, Anthem Biosciences Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Anthem Biosciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Anthem Biosciences Ltd is 83.09. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Revenue from operations (consolidated) for the quarter ended 30 June 2026 was ₹418.22 crore.

Consolidated revenue from operations for the quarter ended 30 June 2026 was ₹418.22 crore.

Investors bought 1,71,14,604 shares, representing a 3.05% stake, at an average price of ₹744.80 per share.

Promoter Aruna Ganesh sold 1,71,14,604 shares, representing a 3.05% stake, and exited the company.